Novartis NOVN.SW
Novartis is a diversified Swiss pharmaceutical company that develops and commercializes innovative medicines in oncology, immunology, neuroscience, and rare diseases, with a business model based on R&D and patents. Novartis shows solid financial health (DN/EBITDA 1.79, operating margin 34.62%) and exceptional quality (ROE 30.35%), but earnings growth is negative (-17%) and valuation (PER 22.19) does not discount an imminent improvement.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Novartis is a diversified Swiss pharmaceutical company that develops and commercializes innovative medicines in oncology, immunology, neuroscience, and rare diseases, with a business model based on R&D and patents. Novartis shows solid financial health (DN/EBITDA 1.79, operating margin 34.62%) and exceptional quality (ROE 30.35%), but earnings growth is negative (-17%) and valuation (PER 22.19) does not discount an imminent improvement.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.8 |
| Quality / Moat | 8.2 |
| Valuation | 5.2 |
| Growth | 2.5 |
| Dividend | 6.3 |
| Momentum | 5.9 |
| Risk & Context | 7.9 |
OVERALL SCORE: 6.3/10
Context and risks
Moderate regulatory and governance risk in Switzerland. Additionally, the pause in CAR-T studies and drug pricing pressure in key markets add specific regulatory uncertainty to the sector.
News considered in the analysis
- Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? — La pausa en estudios de CAR-T autoinmune es un revés regulatorio/científico material para una plataforma clave, aunque el impacto en beneficios a corto plazo es limitado.
- Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines — Indica que Novartis está pagando primas por plataformas tecnológicas, lo que refuerza su pipeline a largo plazo pero presiona la creación de valor a corto.
- A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team — La crítica de un accionista importante sobre la disciplina en M&A añade presión sobre la estrategia de asignación de capital, pero es una opinión, no un hecho consumado.
- Health Care Roundup: Market Talk — Listículo sin información nueva sobre Novartis.
- Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline — Licencia global para terapia radioligante es un movimiento estratégico material que amplía su pipeline oncológico de alto valor.
Verdict: Hold; quality and the oncology pipeline (radioligand therapy) offset short-term weakness, but lack of growth and regulatory risks limit upside potential.
Main risk: The main risk is the slowdown in earnings growth (-17%) and regulatory pricing pressure, which could erode the operating margin and valuation premium.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →